The rollercoaster ride that led to Dynavax stock skyrocketing 74%
July 31, 2017 at 12:18 PM EDT
Safety concerns held the company’s hepatitis B vaccine from approval, but a FDA safety committee just voted in its favor.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|